UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant’s name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
‘Company‘)
Vesting of 2023 Performance Share Plan Award
This notification sets out the vesting details of a conditional
share award made under the GSK 2017 Performance Share Plan (‘PSP’)
to the Chief Financial Officer (CFO) on 27 April 2023 upon her
joining GSK as CFO Designate.
Following the third anniversary of the grant, this 2023 PSP award
has now vested on the same basis as the 2023 PSP awards which
vested on 13 February 2026, with 82% vesting and 18% lapsed.
Details of the performance measure outcomes and vesting levels are
set out in the announcement of 17 February
2026.
For the CFO, the vested shares are subject to an additional
two-year holding period.
The notification that follows details the number of shares that
vested under this 2023 PSP award for the CFO, including dividends
accrued, on 27 April 2026. The balance of the award has
lapsed.
The closing price of Ordinary Shares of GSK plc on the vesting date
was £20.16.
Transaction notification
1.
Details of PDMR/person closely associated with them
(‘PCA’)
a)
Name
Julie Brown
b)
Position/status
Chief Financial Officer
c)
Initial
notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a)
Name
GSK plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
a)
Description
of the financial instrument
Ordinary Shares of 31 ¼ pence each (‘Ordinary
Shares’)
ISIN: GB00BN7SWP63
b)
Nature
of the transaction
The vesting of awards granted in 2023 under the Company’s 2017
Performance Share Plan
c)
Price(s)
and volume(s)
Price(s)
Volume(s)
£0.00
243,880
d)
Aggregated
information
N/A (single transaction)
Aggregated
volume Price
e)
Date
of the transaction
2026-04-27
f)
Place
of the transaction
N/A
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
GSK plc
(Registrant)
Date: April
28, 2026
By:/s/ VICTORIA
WHYTE
————————–
Victoria Whyte
Authorised
Signatory for and on
behalf
of GSK plc
